DeltaznuADeltapurE Brucella abortus 2308 mutant as a live vaccine candidate.
To create a new, safe brucellosis live vaccine, a double mutant strain was constructed from Brucella abortus 2308. Using the DeltaznuA B. abortus 2308 mutant, a second mutation was introduced by deleting purE gene. The DeltaznuA DeltapurE B. abortus 2308 strain was less capable of surviving in macrophages. When evaluated in vivo, it was cleared within 8 weeks (wks) from mice, causing significantly less inflammation than spleens obtained from wild-type B. abortus 2308-infected mice. Furthermore, two doses of DeltaznuA DeltapurE B. abortus 2308 conferred 0.79 log protection, similar to S19 as did a single dose of DeltaznuA B. abortus 2308. Thus, this study shows the DeltaznuA DeltapurE B. abortus 2308 strain to be a potential livestock vaccine candidate.
Yang
Xinghong
X
Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717-3610, USA.
Thornburg
Theresa
T
Walters
Nancy
N
Pascual
David W
DW
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics*; D002004:Brucella Vaccine / Q000235:genetics* / Q000276:immunology*; D002003:Brucella abortus / Q000235:genetics* / Q000276:immunology* / Q000472:pathogenicity; D002006:Brucellosis / Q000382:microbiology / Q000473:pathology; D005260:Female; D017353:Gene Deletion; D007117:Immunization, Secondary / Q000379:methods; D008264:Macrophages / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D050296:Microbial Viability; D013154:Spleen / Q000473:pathology; D014611:Vaccination / Q000379:methods; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D014774:Virulence
D001426:Bacterial Proteins; D002004:Brucella Vaccine; D014613:Vaccines, Attenuated